The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)
Phase 2
Completed
- Conditions
- Atherosclerosis
- Interventions
- Drug: MK0633
- Registration Number
- NCT00421278
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 180
Inclusion Criteria
- Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease
- Inflammatory marker found in your blood, known as hsCRP > 0.5 mg/L
Read More
Exclusion Criteria
- Age < 40 or > 85
- Female
- Heart attack, coronary artery bypass, stroke or unstable angina in last 3 months
- Liver diseased or abnormalities
- HIV infection
- Lupus, rheumatoid arthritis, cancer <5 years
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 MK0633 Arm 1: Drug
- Primary Outcome Measures
Name Time Method To evaluate the effects of the drug, MK 0633, on an inflammatory marker in your blood that may affect the plaque in the arteries, know as atherosclerosis 4 Weeks
- Secondary Outcome Measures
Name Time Method